Quest Diagnostics (DGX) Reports In-Line Q2 EPS; Trims FY12 Revs Growth Outlook
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $238.87 +0.46%
Financial Fact:
Income tax expense: -95M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Income tax expense: -95M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Quest Diagnostics, Inc. (NYSE: DGX) reported Q2 EPS of $1.17, in-line with the analyst estimate of $1.17. Revenue for the quarter came in at $1.91 million versus the consensus estimate of $1.94 million.
Sees FY12 revenues to grow between 1% and 2%, compared to the prior outlook of between 2% and 2.5%.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.
Sees FY12 revenues to grow between 1% and 2%, compared to the prior outlook of between 2% and 2.5%.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
